HDAC9 - histone deacetylase 9 Gene

Rattus norvegicus

Also known as MITR; RGD1310748; RGD1563092

Gene ID: 687001 | Gene type: protein coding

About HDAC9

Primary_assembly 6: 50,763,590-51,625,333 reverse strand.mRatBN7.2:CM026979.1

This gene has 4 transcripts (splice variants), 235 orthologues, 12 paralogues and is associated with 4 phenotypes. Biased expression in Spleen (RPKM 53.7), Heart (RPKM 45.8) and 9 other tissues.

Summary

Predicted to enable several functions, including Enzyme binding activity; histone deacetylase activity (H4-K16 specific); and transcription corepressor activity. Involved in neuron differentiation and response to amphetamine. Located in nucleus. Biomarker of middle cerebral artery infarction. Orthologous to human HDAC9 (histone deacetylase 9). [provided by Alliance of Genome Resources, Apr 2022]

HDAC9 Products(1)

mRNA	Protein	Name
NM_001200045.1	NP_001186974.1	histone deacetylase 9

Gene Ontology

Biological Process

Biological Process GO Annotation	Evidence	Reference	Source
involved in neuron differentiation	IEP IEP: Inferred from expression pattern	12850547	RGD
involved in response to amphetamine	IEP IEP: Inferred from expression pattern	25452209	RGD

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

HDAC9 Protein Structure

ClassIIa_HDAC9_Gln-rich-N

HDAC_classIIa

0
200
400
600
800
1000
1094 a.a.

Protein Preferred Names

Protein Names

histone deacetylase 9

MEF2-interacting transcriptional repressor

Related Agents

Approval

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-13322	Pracinostat	Inhibitor	99.82%	Yes

Clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Phase
HY-14842	Givinostat	Inhibitor	98.16%	Phase 3
HY-14842B	Givinostat hydrochloride monohydrate	Inhibitor	≥98.0%	Phase 3
HY-14842A	Givinostat hydrochloride	Inhibitor	98.06%	Phase 3
HY-15433	Quisinostat	Inhibitor	98.34%	Phase 2
HY-13522	Fimepinostat	Inhibitor	99.95%	Phase 2
HY-15433A	Quisinostat dihydrochloride	Inhibitor	98.28%	Phase 2
HY-16012A	Domatinostat	Inhibitor	99.43%	Phase 2
HY-16012	Domatinostat tosylate	Inhibitor	99.66%	Phase 2
HY-10223	CUDC-101	Inhibitor	98.84%	Phase 1

Pre-clinical Phase

Bioactive Molecules (23)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-18361	TMP195	Inhibitor	99.57%	Unkown
HY-13428	Tubacin	Inhibitor	99.54%	Unkown
HY-18360	TMP269	Inhibitor	98.05%	Unkown
HY-16699	Nexturastat A	Inhibitor	98.28%	Unkown
HY-115475	SW-100	Inhibitor	99.59%	Unkown
HY-119939	CHDI-390576	Inhibitor	98.07%	Unkown
HY-112719	BRD 4354	Inhibitor	99.66%	Unkown
HY-149285	NT160	Inhibitor	99.58%	Unkown
HY-112719B	BRD 4354 ditrifluoroacetate	Inhibitor	98.06%	Unkown
HY-117554	BRD9757	Inhibitor	99.75%	Unkown
HY-146678	HDAC6-IN-5	Inhibitor	/	Unkown
HY-146679	HDAC6-IN-6	Inhibitor	/	Unkown
HY-150109	Purinostat mesylate	Inhibitor	/	Unkown
HY-15144B	(S)-Trichostatin A	Inhibitor	/	Unkown
HY-163803	CM-444	Inhibitor	/	Unkown
HY-149208	HDAC-IN-53	Inhibitor	/	Unkown
HY-152226	MC2590	Inhibitor	/	Unkown
HY-149283	JAK/HDAC-IN-2	Inhibitor	/	Unkown
HY-157740	XSJ-10	Inhibitor	/	Unkown
HY-146684	HDAC-IN-36	Inhibitor	/	Unkown
HY-152225	MC2625	Inhibitor	/	Unkown
HY-169259	HDAC9-IN-1	Inhibitor	/	Unkown
HY-150595	HDAC6-IN-10	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	HDAC9	NCBI	NCBI:9734

Name
Email *

	Sorry, but the email address you supplied was invalid.